Becker's Healthcare November 22, 2021
Katie Adams

Merck completed its acquisition of Acceleron Pharma for about $11.5 billion, the drugmaker said Nov. 22.

Merck announced its plan to acquire Acceleron in September, saying it would pay $180 per share in cash.

The acquisition expands Merck’s rare disease drug portfolio, as it allows the company to take over Acceleron’s lead drug candidate, sotatercept. Merck will also gain access...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma, Pharma / Biotech, Trends
Brazil’s plan for low-cost CAR-Ts
PacBio’s Repeat Expansion Panel, Owkin-Sanofi AI Take on Immunology, More
STAT+: Borrowing an idea from cancer immunotherapy, scientists make old-mice immune systems youthful again
Moderna gets Blackstone backing for flu vaccine R&D
FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertension

Share This Article